Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

Machine learning pipeline for the prediction of Alzheimer’s disease conversion.

More »

Fig 1 Expand

Fig 2.

Censored and uncensored data distribution per year in early and late MCI individuals.

More »

Fig 2 Expand

Table 1.

Number of missing values in features of eMCI and lMCI datasets.

More »

Table 1 Expand

Fig 3.

Distribution of censored and uncensored data in eMCI and lMCI groups.

More »

Fig 3 Expand

Fig 4.

Balancing the training set of eMCI group.

More »

Fig 4 Expand

Fig 5.

Comparison of survival curves of eMCI and lMCI groups showing varying survival probabilities.

More »

Fig 5 Expand

Table 2.

Data statistics of eMCI and lMCI groups in this study.

More »

Table 2 Expand

Table 3.

Best performing hyperparameters obtained using Grid Search-CV.

More »

Table 3 Expand

Fig 6.

Heatmap showing performance of models measured by C-Index and IBS for early MCI.

More »

Fig 6 Expand

Fig 7.

Heatmap showing performance of models measured by C-Index and IBS for late MCI.

More »

Fig 7 Expand

Fig 8.

Feature importance results of eMCI dataset.

The error bars show the standard deviation, and each bar indicates the mean score.

More »

Fig 8 Expand

Fig 9.

Feature importance results of lMCI dataset.

The error bars show the standard deviation, and each bar indicates the mean score.

More »

Fig 9 Expand

Fig 10.

Predicted survival estimates for subjects with (a) progressive eMCI and (b) non-progressive eMCI. The red line refers to the actual event times for progressive/uncensored patients and the actual censoring time for non-progressive/censored patients.

More »

Fig 10 Expand

Fig 11.

Predicted survival estimates for subjects with (c) progressive lMCI and (d) non-progressive lMCI. The red line refers to the actual event times for progressive/uncensored patients and the actual censoring time for non-progressive/censored patients.

More »

Fig 11 Expand

Table 4.

RSF’s performance before and after applying data balancing.

More »

Table 4 Expand